Manal Mustafa

Manal Mustafa

Auto-generated profile, based on publicly available information

Manal Mustafa

Pediatric Endocrinology Department, Al Jalila Children’s Specialty Hospital, Dubai Health, P.O. Box 7662 , Dubai

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
MAMohammad Hosny Awad
Mohammad Hosny Awad
RGReham Ghanim
Reham Ghanim
RERania Eladl
Rania Eladl
ZMZulf Mughal
Zulf Mughal
MMManal Mustafa
Manal Mustafa
Growth hormone deficiency (GHD) in children results in short stature and impaired bone health. While daily growth hormone (GH) injections are effective, they are associated with adherence challenges. Somatrogon, a long-acting recombinant human GH, allows weekly administration, potentially improving treatment compliance. This retrospective cohort study included 39 prepubertal children with GHD treated with weekly Somatrogon at Al Jalila Children's Hospital, Dubai. Diagnosis was based on clinical, biochemical, and radiological criteria, including height standard deviation score (SDS) < -2.0, subnormal growth velocity, and subnormal peak GH in one stimulation test (<10 ng/mL) supported by low IGF-1 and/or abnormal MRI. Growth outcomes and bone health indices were assessed over 12 months using auxology, IGF-1 levels, and BoneXpert-derived Bone Health Index (BHI) SDS and Metacarpal Index (MCI) SDS. After 12 months of therapy, mean height SDS improved significantly from -2.16 ± 0.80 to -1.65 ± 0.71 (p < 0.001). IGF-1 SDS rose from -1.38 ± 1.02 to 0.88 ± 1.57 (p < 0.001). Adult predicted height and BHI SDS also improved significantly (p = 0.005 and p < 0.001, respectively). No significant changes were observed in bone age SDS or MCI SDS. Weekly Somatrogon significantly improved linear growth, IGF-1 levels, and cortical bone health without advancing bone age in children with GHD. These findings support the efficacy of long-acting GH therapy and its potential to optimize growth and skeletal outcomes in clinical practice.

30 April 2024 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MMManal Mustafa
Manal Mustafa
MAMira Almheiri
Mira Almheiri
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease affecting lipoprotein metabolism. FCS is estimated to occur in 1 in 1–2 million individuals and can be diagnosed at any age, equally affecting all genders, races, and ethnicities. The condition is characterized by hypertriglyceridemia, which may predispose patients to acute pancreatitis. In this report, we present the case of a now 6-year-old girl with FCS on gemfibrozil and dietary restrictions. The patient initially presented at 40 days of age with bloody diarrhea. Serum samples revealed lipemia, with markedly elevated triglyceride levels. The patient was diagnosed with FCS, confirmed by genetic testing showing the homozygous variant c.833C>T(p,Ser278Phe) for the LPL gene. Despite being on a low-fat diet with medium chain triglyceride (MCT) based milk formulas, the patient developed acute pancreatitis 2 months later with continued elevated triglyceride levels. She was placed on gemfibrozil and fat-soluble vitamins at 2 months of age, with marked improvements subsequently noted. Currently, the patient is doing well, with normal growth parameters and no other episodes of acute pancreatitis. Her triglyceride levels have been maintained within normal levels. FCS is a rare, inherited lipid disorder that often goes underdiagnosed and unmanaged. It is worth considering the fibric acid derivative (gemfibrozil) to be one of the lines of management early on after diagnosis.

1 January 2025 in Pediatric Diabetes
Verified
Journal Article
Open access
NANajyya Attia
Najyya Attia
KNKhalid Al Noaim
Khalid Al Noaim
MMManal Mustafa
Manal Mustafa
SFSuliman H. Al Fifi
Suliman H. Al Fifi
IAIBRAHIM ALWAN ALALWAN
IBRAHIM ALWAN ALALWAN
ABAmir Babiker
Amir Babiker
Background: Managing severe insulin resistance (IR) is challenging, necessitating a multifaceted approach, including dietary restriction, exercise, and pharmacotherapy. This paper will detail our utilization of dapagliflozin in a series of cases involving patients with severe IR of various etiology and inadequate glycemic control. Case Studies: We describe six cases of extreme IR with distinct clinical diagnoses: four with Rabson–Mendenhall syndrome (RMS), one with IR type 1A, and a patient with type 1 diabetes mellitus (T1DM) and severe subcutaneous (SC) IR. These cases exhibit the observable characteristics of IR, characterized by an inability to effectively manage blood glucose (BG) with a standard treatment plan. Every case had a remarkable response to dapagliflozin. Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C‐peptide concentrations. Furthermore, several cases demonstrated improvement in the clinical manifestations of IR following the administration of dapagliflozin, while others showed a reduction in the frequency of diabetic ketoacidosis (DKA). There were no documented adverse reactions with the use of dapagliflozin for a duration of 2–4 years in these patients. Conclusion: Dapagliflozin appeared both safe and effective as a standalone treatment or when used alongside other antidiabetes medications such as insulin in a case series of children with T1DM and severe IR or IR syndromes (IRS).

13 December 2022 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
MJMaryam Jafari
Maryam Jafari
AHAhmedyar Hasan
Ahmedyar Hasan
JJJessie Joseph
Jessie Joseph
MMManal Mustafa
Manal Mustafa
SASamar AlMuntaser
Samar AlMuntaser
Diabetic neuropathy is a major cause of morbidity among diabetics, usually affecting patients with long-standing diabetes and advancing age. We present a case of atypical first clinical presentation of type 1 diabetes mellitus (T1DM) in a pediatric patient. A 15-year-old male patient presented to the emergency department with complaints of right foot weakness associated with mild paresthesia of 1-week duration. There were complaints of polyuria, polydipsia and weight loss in the same timeframe. On subsequent examination, the patient exhibited signs of right-sided foot drop with weak ankle dorsiflexion and eversion, accompanied by impaired sensation over the dorsum of the right foot. Lab results confirmed a diagnosis of T1DM and the patient was started on subcutaneous insulin injections. The patient's foot drop recovered within one month of insulin initiation. This case highlights that T1DM may present atypically as acute onset neuropathy in pediatric patients, making it an important differential diagnosis.

1 January 2020 in Journal of Pediatrics & Neonatal Care
Verified
Journal Article
Open access
PDF file
MKManal Mustafa Khadora
Manal Mustafa Khadora
Autoimmune thyroiditis (Hashimoto thyroiditis) is the commonest thyroid disorder in childhood. It is associated with antibodies against thyroglobulin and thyroperoxidase with lymphocytic infiltration in the thyroid tissue. It may be associated with primary hypothyroidism, transient hyperthyroidism or an euthyroid state. It typically affects females-5 times more commonly than males. We aim to describe three rare presentations of a common disease (Hashimoto thyroiditis) in the same child and to discuss its clinical course and response to L-Thyroxin replacement during two years of treatment. We report an eleven years six months old female child, with severe long standing acquired primary hypothyroidism due to Hashimoto thyroiditis, who had, in addition to the typical hypothyroidism symptoms, three rare presentations at the same time including Hashimoto encephalopathy, gonadotropin independent precocious puberty and pituitary adenoma. She was treated with L-Thyroxin only with significant improvement and regression of her symptoms.

25 August 2026 in JBMR Plus
Verified
Journal Article
Open access
MAMohammad Hosny Awad
Mohammad Hosny Awad
RERania Eladl
Rania Eladl
AAAsmahan Tagelsir Abdalla
Asmahan Tagelsir Abdalla
IMIbrar Majid
Ibrar Majid
MKMohamed Kenaway
Mohamed Kenaway
MMMohamed Zulficar Mughal
Mohamed Zulficar Mughal
Bruck syndrome is a rare autosomal recessive form of OI caused by biallelic variants in FKBP10 or PLOD2, and characterized by fragility fractures with congenital or progressive joint contractures. We describe 13 patients from 2 tertiary pediatric centers in the United Arab Emirates and report exploratory health-related quality-of-life data using the Pediatric Quality of Life Inventory (PedsQL). Published molecularly confirmed cases were reviewed solely to contextualize the cohort. The cohort comprised 13 patients (7 female and 6 male; median age, 4 yr; range, 13 mo-14 yr) from 11 unrelated families, including 2 sibling pairs. Twelve patients had FKBP10 variants and 1 had PLOD2 variants. FKBP10 c.831dup was identified in 10 patients from 8 unrelated families of Emirati, Sudanese, and Indian backgrounds. Recurrent long-bone fractures occurred in 11 patients (85%), joint contractures in 6 (46%), and vertebral deformity in 9 (69%). Mobility ranged from independent ambulation to nonambulatory status, including among patients carrying c.831dup. The PedsQL domain scores (mean ± SD) were 47.2 ± 23.7 for physical functioning, 72.7 ± 19.3 for emotional functioning, 57.7 ± 22.5 for social functioning, and 64.5 ± 25.0 for school functioning. Physical functioning had the lowest mean domain score; these findings are descriptive because of the small, age-heterogeneous cohort, and the limitations of a single generic instrument. This 2-center case series expands the reported phenotypic and functional spectrum of FKBP10- and PLOD2-related diseases. The FKBP10 c.831dup variant was identified across 3 national backgrounds in the UAE cohort and has been reported in other populations, supporting its interpretation as a recurrent variant brought into homozygosity by regional consanguinity rather than a UAE-specific founder mutation. The variability in skeletal severity, mobility, and functional outcome, including among patients sharing the same variant, highlights the need for individualized multidisciplinary care addressing fracture prevention, mobility, spinal surveillance, rehabilitation, and long-term function.